(Q38765030)

6 September 2017

1 reference

title

Quinolones and the gastrointestinal tract (English)

1 reference

6 September 2017

0 references

B E Murray

1

1 reference

6 September 2017

publication date

1 December 1989

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

6 September 2017

published in

1 reference

6 September 2017

volume

8

1 reference

6 September 2017

issue

12

1 reference

6 September 2017

page(s)

1093-1101

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01975176

6 September 2017

exact match

0 references

cites work

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Norfloxacin binds to human fecal material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Effect of oral ofloxacin on fecal bacteria in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Effects of erythromycin and ciprofloxacin on chronic fecal excretion of Campylobacter species in marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Open, prospective study of the clinical efficacy of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Efficacy of Ciprofloxacin in the Treatment of Chronic Typhoid Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Use of norfloxacin to treat chronic typhoid carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Hepatobiliary kinetics and excretion of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Concentration of norfloxacin in human gallbladder tissue and bile after single-dose oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975176

Treatment of chronic salmonella carriers with ciprofloxacin

21 January 2018

1 reference

12 December 2020

Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

1 reference

12 December 2020

Intestinal microflora changes induced by ciprofloxacin and treatment of portal-systemic encephalopathy (PSE)

1 reference

12 December 2020

Norfloxacin in the treatment of bacterial enteric infections.

1 reference

12 December 2020

Ciprofloxacin and antacids

1 reference

12 December 2020

Impact of fluoroquinolones on the gastrointestinal flora

1 reference

12 December 2020

The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens

1 reference

12 December 2020

Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient

1 reference

12 December 2020

Reduced enteral absorption of ciprofloxacin in the presence of antacids

1 reference

12 December 2020

Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults

1 reference

12 December 2020

Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics

1 reference

12 December 2020

Short-term ciprofloxacin therapy for typhoid fever

1 reference

12 December 2020

Effect of enoxacin on colonic microflora of healthy volunteers

1 reference

12 December 2020

Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis

1 reference

12 December 2020

Ofloxacin in treatment of typhoid fever: a preliminary study.

1 reference

12 December 2020

Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis

1 reference

12 December 2020

Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections

1 reference

12 December 2020

In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria

1 reference

12 December 2020

Prevention of bacterial infections after bone marrow graft by broad-spectrum oral antibiotics, absorbable (pefloxacin, penicillin) and non absorbable (cephalosporin, gentamycin, bacitracin)

1 reference

12 December 2020

Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa

1 reference

12 December 2020

Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration.

1 reference

12 December 2020

Norfloxacin for prevention of bacterial infections in granulocytopenic patients

1 reference

12 December 2020

Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

1 reference

12 December 2020

Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora.

1 reference

12 December 2020

Problems in identification of Campylobacter jejuni associated with acquisition of resistance to nalidixic acid.

1 reference

12 December 2020

Use of norfloxacin in the treatment of acute diarrheal disease

1 reference

12 December 2020

Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis

1 reference

12 December 2020

Quinolones: a new class of antimicrobial agents with wide potential uses

1 reference

12 December 2020

Rapid improvement of hepatic encephalopathy associated with oral ciprofloxacin treatment

1 reference

12 December 2020

Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.

1 reference

12 December 2020

A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients

1 reference

12 December 2020

The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

1 reference

12 December 2020

The new fluorinated quinolones for infection prevention in acute leukemia

1 reference

12 December 2020

Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea

1 reference

12 December 2020

Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea

1 reference

12 December 2020

Treatment of sonne dysentery

1 reference

12 December 2020

Use of ciprofloxacin in biliary sepsis.

1 reference

12 December 2020

Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia

1 reference

12 December 2020

Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin

1 reference

12 December 2020

Biliary tract excretion of ofloxacin in man.

1 reference

12 December 2020

Successful treatment with ciprofloxacin of Salmonella typhimurium infection in an immunocompromised host.

1 reference

12 December 2020

Impact of oral ciprofloxacin on the faecal flora of healthy volunteers

1 reference

12 December 2020

A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora

1 reference

12 December 2020

Effect of oral ciprofloxacin on the faecal flora of healthy volunteers.

1 reference

12 December 2020

Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections

1 reference

12 December 2020

Effect of ofloxacin on oral and gastrointestinal microflora in patients undergoing gastric surgery

1 reference

12 December 2020

Successful treatment of chronic Salmonella excretor with ofloxacin.

1 reference

12 December 2020

Bismuth/ofloxacin combination for duodenal ulcer

1 reference

12 December 2020

Norfloxacin in the eradication of enteric infections in AIDS patients.

1 reference

12 December 2020

Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.

1 reference

12 December 2020

Ciprofloxacin for cholangitis after hepatic portoenterostomy

1 reference

12 December 2020

Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment.

1 reference

12 December 2020

Influence of quinolones on throat- and faecal flora of healthy volunteers

1 reference

12 December 2020

Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome.

1 reference

12 December 2020

The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms

1 reference

12 December 2020

Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients

1 reference

12 December 2020

Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.

1 reference

12 December 2020

Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract

1 reference

12 December 2020

Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach

1 reference

12 December 2020

Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01975176

1 reference

Dimensions Publication ID

6 September 2017

1017788122

0 references

1 reference